Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy

被引：16

作者：

Bouziana, Stella ^{[1
]}

Bouzianas, Dimitrios ^{[2
]}

机构：

[1] G Papanikolaou Hosp, Dept Hematol, BMT Unit, Thessaloniki 57010, Greece

[2] BReMeL Biopharmaceut & Regenerat Med Labs, Thessaloniki, Greece

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2021年 / 157卷

关键词：

CAR-T cells; Acute lymphoblastic leukemia; Non-Hodgkin lymphoma; Resistance mechanisms; Relapse; Antigen escape; CHIMERIC ANTIGEN RECEPTORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL; ADOPTIVE IMMUNOTHERAPY; CD19; RESISTANCE; EXPANSION; CD8(+); REMISSIONS; EXPRESSION;

D O I：

10.1016/j.critrevonc.2020.103096

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The unprecedented technological advances in genetic engineering have resulted in the advent of the very promising chimeric antigen receptor (CAR)-T cell therapy. Based on the striking outcomes of clinical trials, the first two commercial CAR-T cell products, tisagenlecleucel and axicabtagene ciloleucel, have been approved in both the United States and Europe for the treatment of patients with highly aggressive CD19-positive hematological malignancies. Despite the initial remarkable responses many patients finally relapse, implying the presence of resistance mechanisms. In this review, we describe the limitations and resistance mechanisms to antiCD19 CAR-T cells and address potential strategies to overcome CAR-T cell barriers.

引用

页数：12

共 158 条

[1] Strategies to Address Chimeric Antigen Receptor Tonic Signaling [J].

Ajina, Adam ;

Maher, John .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (09) :1795-1815

[2] CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells [J].

Alcantara, Marion ;

Tesio, Melania ;

June, Carl H. ;

Houot, Roch .

LEUKEMIA, 2018, 32 (11) :2307-2315

[3] The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma [J].

Ali, Sahra ;

Kjeken, Rune ;

Niederlaender, Christiane ;

Markey, Greg ;

Saunders, Therese S. ;

Opsata, Mona ;

Moltu, Kristine ;

Bremnes, Bjorn ;

Gronevik, Eirik ;

Muusse, Martine ;

Hakonsen, Gro D. ;

Skibeli, Venke ;

Kalland, Maria Elisabeth ;

Wang, Ingrid ;

Buajordet, Ingebjorg ;

Urbaniak, Ania ;

Johnston, John ;

Rantell, Khadija ;

Kerwash, Essam ;

Schuessler-Lenz, Martina ;

Salmonson, Tomas ;

Bergh, Jonas ;

Gisselbrecht, Christian ;

Tzogani, Kyriaki ;

Papadouli, Irene ;

Pignatti, Francesco .

ONCOLOGIST, 2020, 25 (02) :E321-E327

[4] IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype [J].

Alizadeh, Darya ;

Wong, Robyn A. ;

Yang, Xin ;

Wang, Dongrui ;

Pecoraro, Joseph R. ;

Kuo, Cheng-Fu ;

Aguilar, Brenda ;

Qi, Yue ;

Ann, David K. ;

Starr, Renate ;

Urak, Ryan ;

Wang, Xiuli ;

Forman, Stephen J. ;

Brown, Christine E. .

CANCER IMMUNOLOGY RESEARCH, 2019, 7 (05) :759-772

[5] Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study [J].

Amrolia, Persis J. ;

Wynn, Robert ;

Hough, Rachael E. ;

Vora, Ajay ;

Bonney, Denise ;

Veys, Paul ;

Chiesa, Robert ;

Rao, Kanchan ;

Clark, Liz ;

Al-Hajj, Muhammad ;

Cordoba, Shaun P. ;

Onuoha, Shimobi ;

Kotsopoulou, Ekaterini ;

Khokhar, Nushmia Z. ;

Pule, Martin ;

Peddareddigari, Vijay G. R. .

BLOOD, 2019, 134

[6]

[Anonymous], 2018, GKYH1182643

[7]

[Anonymous], 2018, J CLIN ONCOL

[8]

[Anonymous], Blood, DOI DOI 10.1182/BLOOD-2018-99-116653

[9]

[Anonymous], 2019, BLOOD S1, DOI DOI 10.1182/BLOOD-2019-125328

[10]

[Anonymous], 2017, BLOOD S1

← 1 2 3 4 5 6 7 8 9 10 →